CSL Seqirus to Highlight Commitment to Influenza Protection with More than 20 Data Presentations at OPTIONS XI
Data derived from a broad range of seasonal and pandemic influenza studies, including an oral presentation of influenza risk factors, will be shared.
- Data derived from a broad range of seasonal and pandemic influenza studies, including an oral presentation of influenza risk factors, will be shared.
- "At CSL Seqirus, vaccine innovation is in our DNA, which is reflected in our strong presence at OPTIONS XI," said S. Raja Rajaram, M.D., Head of Global Medical Strategy, CSL Seqirus.
- Cost-Effectiveness of Quadrivalent Adjuvanted Influenza Vaccine with MF59 Versus a Standard-Dose Quadrivalent Influenza Vaccines in Spain.
- Today, CSL including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor provides lifesaving products to patients in more than 100 countries and employs 30,000 people.